| Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial 2013 · lutein + zeaxanthin group · Adults aged 50 to 85 years at risk for progression to advanced age-related macular degeneration, with bilateral large drusen or large drusen in one eye and advanced AMD in the fellow eye | 2 mg | 10 mg | 5 years | — |
| Secondary analyses of the effects of lutein/zeaxanthin on age-related macular degeneration progression: AREDS2 report No. 3 2014 · lutein/zeaxanthin · Adults with high risk of progression to late age-related macular degeneration; mean age 73.1 years; sex not specified | 2 mg | 10 mg | 1789 days | — |
| No CFH or ARMS2 Interaction with Omega-3 Fatty Acids, Low versus High Zinc, or β-Carotene versus Lutein and Zeaxanthin on Progression of Age-Related Macular Degeneration in the Age-Related Eye Disease Study 2: Age-Related Eye Disease Study 2 Report No. 18 2019 · Lutein and zeaxanthin addition · Adults with bilateral large drusen or late AMD in one eye and large drusen in the fellow eye | 2 mg | 10 mg | 5 years | — |
| Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial 2013 · lutein + zeaxanthin and DHA + EPA group · Adults aged 50 to 85 years at risk for progression to advanced age-related macular degeneration, with bilateral large drusen or large drusen in one eye and advanced AMD in the fellow eye | 2 mg | 10 mg | 5 years | — |
| Secondary analyses of the effects of lutein/zeaxanthin on age-related macular degeneration progression: AREDS2 report No. 3 2014 · lutein/zeaxanthin and DHA/EPA · Adults with high risk of progression to late age-related macular degeneration; mean age 73.1 years; sex not specified | 2 mg | 10 mg | 1789 days | — |
| No CFH or ARMS2 Interaction with Omega-3 Fatty Acids, Low versus High Zinc, or β-Carotene versus Lutein and Zeaxanthin on Progression of Age-Related Macular Degeneration in the Age-Related Eye Disease Study 2: Age-Related Eye Disease Study 2 Report No. 18 2019 · Lutein and zeaxanthin plus omega-3 fatty acids · Adults with bilateral large drusen or late AMD in one eye and large drusen in the fellow eye | 2 mg | 10 mg | 5 years | — |
| Supplemental Retinal Carotenoids Enhance Memory in Healthy Individuals with Low Levels of Macular Pigment in A Randomized, Double-Blind, Placebo-Controlled Clinical Trial 2018 · active group · Healthy individuals with low macular pigment levels; mean age 45.42 years, 51.6% male | 2 mg | 10 mg | 1 year | 45 |
| Effects of a Lutein and Zeaxanthin Intervention on Cognitive Function: A Randomized, Double-Masked, Placebo-Controlled Trial of Younger Healthy Adults 2017 · active supplement group · Healthy adults aged 18–30 years, college students, without a stated diagnosed condition | 2 mg | 10 mg | 1 year | 37 |
| Effects of Astaxanthin, Lutein, and Zeaxanthin on Eye-Hand Coordination and Smooth-Pursuit Eye Movement after Visual Display Terminal Operation in Healthy Subjects: A Randomized, Double-Blind Placebo-Controlled Intergroup Trial 2023 · active group · Healthy Japanese males and females aged 20–60 years who routinely used visual display terminals or played video games | 2 mg | 10 mg | 8 weeks | 32 |
| Effect of supplemental lutein and zeaxanthin on serum, macular pigmentation, and visual performance in patients with early age-related macular degeneration 2015 · lutein (10 mg) + zeaxanthin (10 mg) · Adults aged over 50 with clinically diagnosed early age-related macular degeneration | 10 mg | 10 mg | 2 years | 28 |
| Improvement of retinal function in early age-related macular degeneration after lutein and zeaxanthin supplementation: a randomized, double-masked, placebo-controlled trial 2012 · 10 mg/d lutein plus 10 mg/d zeaxanthin · People with early age-related macular degeneration; age range and sex not reported | 10 mg | 10 mg | 48 weeks | 27 |
| Increases in plasma lutein through supplementation are correlated with increases in physical activity and reductions in sedentary time in older adults 2014 · Lutein · Adults aged 55–80 who were not obese and did not meet physical activity guidelines | 900 mcg | 21 mg | 4 weeks | 19 |
| Effect of Omega-3 Fatty Acids, Lutein/Zeaxanthin, or Other Nutrient Supplementation on Cognitive Function: The AREDS2 Randomized Clinical Trial 2015 · Lutein/zeaxanthin · Older adults with intermediate or late age-related macular degeneration; mean age about 73 years, both sexes | 2 mg | 10 mg | 5 years | — |
| Effects of Long-Chain Polyunsaturated Fatty Acids in Combination with Lutein and Zeaxanthin on Episodic Memory in Healthy Older Adults 2023 · LCPUFAs + LZ group, Trial 2 · Healthy Japanese adults aged 55–79 with memory complaints and no dementia; cognitive-decline subgroup had MoCA-J scores below 23 | 2 mg | 10 mg | 12 weeks | 96 |
| Effects of Long-Chain Polyunsaturated Fatty Acids in Combination with Lutein and Zeaxanthin on Episodic Memory in Healthy Older Adults 2023 · LCPUFAs + LZ group, Trial 1 · Healthy Japanese adults aged 55–79 with memory complaints and no dementia; cognitive-decline subgroup had MoCA-J scores below 23 | 2 mg | 10 mg | 24 weeks | 40 |
| Omega-3 fatty acid, carotenoid and vitamin E supplementation improves working memory in older adults: A randomised clinical trial 2022 · active group · Cognitively healthy adults aged 65 years and older | 2 mg | 10 mg | 2 years | 30 |
| Visual Function and Macular Carotenoid Changes in Eyes with Retinal Drusen-An Open Label Randomized Controlled Trial to Compare a Micronized Lipid-Based Carotenoid Liquid Supplementation and AREDS-2 Formula 2020 · LM group · Adults aged 54–80 with retinal drusen and risk of age-related macular degeneration | 3 mg | 15 mg | 26 weeks | 29 |
| Visual Function and Macular Carotenoid Changes in Eyes with Retinal Drusen-An Open Label Randomized Controlled Trial to Compare a Micronized Lipid-Based Carotenoid Liquid Supplementation and AREDS-2 Formula 2020 · PV group · Adults aged 54–80 with retinal drusen and risk of age-related macular degeneration | 2 mg | 10 mg | 26 weeks | 20 |
| Carotenoids and antioxidants in age-related maculopathy italian study: multifocal electroretinogram modifications after 1 year 2008 · treated AMD (T-AMD) group · Patients with nonadvanced age-related macular degeneration; mean age 69.4 years | 1 mg | 10 mg | 1 year | 15 |
| Effects of Macuprev(®) Supplementation in Age-Related Macular Degeneration: A Double-Blind Randomized Morpho-Functional Study Along 6 Months of Follow-Up 2019 · AMD-M group · Adults with intermediate age-related macular degeneration; 9 male and 21 female enrolled overall, mean age 69.32 years | 4 mg | 20 mg | 26 weeks | 15 |
| Beneficial Effects of Micronutrient Supplementation in Restoring the Altered Microbiota and Gut-Retina Axis in Patients with Neovascular Age-Related Macular Degeneration-A Randomized Clinical Trial 2024 · intervention group · Adults with neovascular age-related macular degeneration; mean age 77.8 years | 2 mg | 10 mg | 26 weeks | 15 |
| Carotenoids in Age-related Maculopathy Italian Study (CARMIS): two-year results of a randomized study 2012 · treated group · Patients with age-related macular degeneration; age and sex not stated | 1 mg | 10 mg | 2 years | — |
| Effect of Omega-3 Fatty Acids, Lutein/Zeaxanthin, or Other Nutrient Supplementation on Cognitive Function: The AREDS2 Randomized Clinical Trial 2015 · DHA/EPA and lutein/zeaxanthin · Older adults with intermediate or late age-related macular degeneration; mean age about 73 years, both sexes | 2 mg | 10 mg | 5 years | — |
| Effect of Dietary Supplementation with Lutein, Zeaxanthin, and Elderberries on Dry Eye Disease (DED) and Immunity: A Randomized Controlled Trial 2024 · intervention group · Adults aged 18 years or older with dry eye symptoms | 1 mg | 6 mg | 20 days | — |
| A double-blind, placebo-controlled study on the effects of lutein and zeaxanthin on photostress recovery, glare disability, and chromatic contrast 2014 · L+Z · Young, healthy subjects; age and sex not specified | 2 mg | 10 mg | 1 year | 57 |
| A double-blind, placebo-controlled study on the effects of lutein and zeaxanthin on neural processing speed and efficiency 2014 · Multi · Healthy adults aged 18–32 years | 26 mg | 8 mg | 120 days | 25 |
| Night Vision and Carotenoids (NVC): A Randomized Placebo Controlled Clinical Trial on Effects of Carotenoid Supplementation on Night Vision in Older Adults 2021 · treatment group · Older US veterans with difficulty seeing at night, without overt ocular disease; mean age 62.7 years | 14 mg | 7 mg | 26 weeks | 24 |
| The effect of modified eggs and an egg-yolk based beverage on serum lutein and zeaxanthin concentrations and macular pigment optical density: results from a randomized trial 2014 · Lutein Egg · Healthy adults aged 18 years and older with macular pigment optical density below 0.55 | 137 mcg | 921 mcg | 90 days | 20 |
| The effect of modified eggs and an egg-yolk based beverage on serum lutein and zeaxanthin concentrations and macular pigment optical density: results from a randomized trial 2014 · Zeaxanthin Egg · Healthy adults aged 18 years and older with macular pigment optical density below 0.55 | 487 mcg | 174 mcg | 90 days | 20 |
| Macular carotenoid supplementation in subjects with atypical spatial profiles of macular pigment 2012 · Group 1 · Healthy subjects with atypical macular pigment spatial profiles; age and sex not stated | 2 mg | 20 mg | 8 weeks | 10 |
| Macular carotenoid supplementation in subjects with atypical spatial profiles of macular pigment 2012 · Group 2 · Healthy subjects with atypical macular pigment spatial profiles; age and sex not stated | 2 mg | 10 mg | 8 weeks | 10 |
| Macular carotenoid supplementation in subjects with atypical spatial profiles of macular pigment 2012 · Group 3 · Healthy subjects with atypical macular pigment spatial profiles; age and sex not stated | 2 mg | 3 mg | 8 weeks | 10 |
| Serum response to supplemental macular carotenoids in subjects with and without age-related macular degeneration 2013 · Group 1 · Adults with or without age-related macular degeneration; age and sex not reported | 2 mg | 20 mg | 8 weeks | — |
| Serum response to supplemental macular carotenoids in subjects with and without age-related macular degeneration 2013 · Group 2 · Adults with or without age-related macular degeneration; age and sex not reported | 2 mg | 10 mg | 8 weeks | — |
| Serum response to supplemental macular carotenoids in subjects with and without age-related macular degeneration 2013 · Group 3 · Adults with or without age-related macular degeneration; age and sex not reported | 2 mg | 3 mg | 8 weeks | — |
| Serum and macular responses to multiple xanthophyll supplements in patients with early age-related macular degeneration 2013 · lutein plus zeaxanthin (LZ) · Chinese patients older than 50 years with early age-related macular degeneration | 10 mg | 10 mg | 48 weeks | — |
| Age-related macular degeneration: Effects of a short-term intervention with an oleaginous kale extract--a pilot study 2013 · kale group · Adults with non-exudative age-related macular degeneration; age range and sex not reported | 3 mg | 10 mg | 4 weeks | — |
| Effect of Long-Term Xanthophyll and Anthocyanin Supplementation on Lutein and Zeaxanthin Serum Concentrations and Macular Pigment Optical Density in Postmenopausal Women 2018 · Group X—xanthophylls · Postmenopausal women aged 50–70 years | 2 mg | 6 mg | 240 days | — |
| Effect of Long-Term Xanthophyll and Anthocyanin Supplementation on Lutein and Zeaxanthin Serum Concentrations and Macular Pigment Optical Density in Postmenopausal Women 2018 · Group X+A—anthocyanines and xanthophylls · Postmenopausal women aged 50–70 years | 2 mg | 6 mg | 240 days | — |
| Systemic Effects of Prenatal Carotenoid Supplementation in the Mother and her Child: The Lutein and Zeaxanthin in Pregnancy (L-ZIP) Randomized Trial -Report Number 1 2023 · Carotenoid group · First-trimester pregnant subjects | 2 mg | 10 mg | 240 days | — |
| Supplementation With Carotenoids, Omega-3 Fatty Acids, and Vitamin E Has a Positive Effect on the Symptoms and Progression of Alzheimer's Disease 2022 · active group · People with mild-moderate Alzheimer's disease; age and sex not reported | 2 mg | 10 mg | 1 year | 50 |
| Lutein and Zeaxanthin Supplementation Improves Dynamic Visual and Cognitive Performance in Children: A Randomized, Double-Blind, Parallel, Placebo-Controlled Study 2024 · LZ group · Children aged 5–12 years, male and female | 2 mg | 10 mg | 180 days | 40 |
| Lutein supplementation increases breast milk and plasma lutein concentrations in lactating women and infant plasma concentrations but does not affect other carotenoids 2014 · low-dose group · Women aged 18 years or older, 4–6 weeks postpartum, continuously lactating and breastfeeding full-term singleton infants | 96 mcg | 6 mg | 6 weeks | 29 |
| Effect of lutein and zeaxanthin on macular pigment and visual function in patients with early age-related macular degeneration 2012 · 10 mg/day lutein plus 10 mg/day zeaxanthin · Adults aged 50–79 with early age-related macular degeneration | 10 mg | 10 mg | 48 weeks | 27 |
| Lutein supplementation increases breast milk and plasma lutein concentrations in lactating women and infant plasma concentrations but does not affect other carotenoids 2014 · high-dose group · Women aged 18 years or older, 4–6 weeks postpartum, continuously lactating and breastfeeding full-term singleton infants | 192 mcg | 12 mg | 6 weeks | 26 |
| Randomized, double-blind, placebo-controlled study of zeaxanthin and visual function in patients with atrophic age-related macular degeneration: the Zeaxanthin and Visual Function Study (ZVF) FDA IND #78, 973 2011 · 8 mg Zx plus 9 mg lutein · Patients with mild-to-moderate age-related macular degeneration, mean age 74.9 years; 57 men and 3 women across the study | 8 mg | 9 mg | 1 year | 25 |
| Supplementation with three different macular carotenoid formulations in patients with early age-related macular degeneration 2014 · Group 2 · People with early age-related macular degeneration; age and sex not stated | 2 mg | 10 mg | 1 year | 21 |
| Changes in Macular Pigment Optical Density and Serum Lutein Concentration in Japanese Subjects Taking Two Different Lutein Supplements 2015 · FloraGLO group · Healthy Japanese adults aged 20 years and older, without ocular or systemic pathologies | 960 mcg | 10.5 mg | 26 weeks | 18 |
| Changes in Macular Pigment Optical Density and Serum Lutein Concentration in Japanese Subjects Taking Two Different Lutein Supplements 2015 · XanMax group · Healthy Japanese adults aged 20 years and older, without ocular or systemic pathologies | 1.29 mg | 10.4 mg | 26 weeks | 18 |
| Supplementation with three different macular carotenoid formulations in patients with early age-related macular degeneration 2014 · Group 1 · People with early age-related macular degeneration; age and sex not stated | 2 mg | 20 mg | 1 year | 17 |
| Goji Berry Intake Increases Macular Pigment Optical Density in Healthy Adults: A Randomized Pilot Trial 2021 · LZ supplement group · Healthy men and women aged 45–65 years with normal macular condition and no signs of drusen or early AMD | 4 mg | 6 mg | 90 days | 15 |
| Supplementation with three different macular carotenoid formulations in patients with early age-related macular degeneration 2014 · Group 3 · People with early age-related macular degeneration; age and sex not stated | 2 mg | 3 mg | 1 year | 14 |
| Supplementation with all three macular carotenoids: response, stability, and safety 2011 · intervention (I group) · healthy adults; age and sex not specified | 1.2 mg | 5.9 mg | 26 weeks | — |
| The impact of macular pigment augmentation on visual performance using different carotenoid formulations 2012 · group 1 · Adults, 19–64 years (mean age 51 years), 19 male and 17 female across the study; condition not specified | 2 mg | 20 mg | 26 weeks | — |
| The impact of macular pigment augmentation on visual performance using different carotenoid formulations 2012 · group 2 · Adults, 19–64 years (mean age 51 years), 19 male and 17 female across the study; condition not specified | 2 mg | 10 mg | 26 weeks | — |
| Macular xanthophylls and ω-3 long-chain polyunsaturated fatty acids in age-related macular degeneration: a randomized trial 2013 · group 1 · Individuals with nonexudative age-related macular degeneration; age and sex not specified | 1 mg | 10 mg | 1 year | — |
| Changes following supplementation with lutein and zeaxanthin in retinal function in eyes with early age-related macular degeneration: a randomised, double-blind, placebo-controlled trial 2015 · lutein (10 mg)+zeaxanthin (10 mg) · Patients with early age-related macular degeneration | 10 mg | 10 mg | 2 years | — |
| The impact of supplemental macular carotenoids in Alzheimer's disease: a randomized clinical trial 2015 · Macushield, Alzheimer's disease patients · Adults with Alzheimer's disease; age range and sex not stated | 2 mg | 10 mg | 26 weeks | — |
| The impact of supplemental macular carotenoids in Alzheimer's disease: a randomized clinical trial 2015 · Macushield, age-similar control subjects · Age-similar control subjects; age range and sex not stated | 2 mg | 10 mg | 26 weeks | — |
| Sustained supplementation and monitored response with differing carotenoid formulations in early age-related macular degeneration 2015 · Group 1 · People with early age-related macular degeneration; age and sex not specified | 860 mcg | 20 mg | 3 years | — |
| Sustained supplementation and monitored response with differing carotenoid formulations in early age-related macular degeneration 2015 · Group 2 · People with early age-related macular degeneration; age and sex not specified | 2 mg | 10 mg | 3 years | — |
| Sustained supplementation and monitored response with differing carotenoid formulations in early age-related macular degeneration 2015 · Group 3 · People with early age-related macular degeneration; age and sex not specified | 2 mg | 3 mg | 3 years | — |
| The effects of lutein and zeaxanthin on resting state functional connectivity in older Caucasian adults: a randomized controlled trial 2020 · Lutein and zeaxanthin supplement · Community-dwelling older adults, mean age 72 years | 2 mg | 10 mg | 1 year | — |
| Lack of a Synergistic Effect on Cardiometabolic and Redox Markers in a Dietary Supplementation with Anthocyanins and Xanthophylls in Postmenopausal Women 2019 · Group X (xanthophylls) · Women aged 50–70 years, postmenopausal for more than two years, with BMI 25–33 kg/m² | 2 mg | 6 mg | 243 days | — |
| Lack of a Synergistic Effect on Cardiometabolic and Redox Markers in a Dietary Supplementation with Anthocyanins and Xanthophylls in Postmenopausal Women 2019 · Group A+X (anthocyanins + xanthophylls) · Women aged 50–70 years, postmenopausal for more than two years, with BMI 25–33 kg/m² | 2 mg | 6 mg | 243 days | — |
| Oral Antioxidant and Lutein/Zeaxanthin Supplements Slow Geographic Atrophy Progression to the Fovea in Age-Related Macular Degeneration 2025 · AREDS2 lutein plus zeaxanthin · Adults aged 50–85 with large drusen in both eyes or late AMD in one eye and large drusen in the fellow eye | 2 mg | 10 mg | 5 years | — |
| Long term effects of lutein, zeaxanthin and omega-3-LCPUFAs supplementation on optical density of macular pigment in AMD patients: the LUTEGA study 2013 · D2 (twice daily) · Patients with non-exudative age-related macular degeneration; age and sex not specified | 2 mg | 20 mg | 1 year | 55 |
| Long term effects of lutein, zeaxanthin and omega-3-LCPUFAs supplementation on optical density of macular pigment in AMD patients: the LUTEGA study 2013 · D1 (once daily) · Patients with non-exudative age-related macular degeneration; age and sex not specified | 1 mg | 10 mg | 1 year | 50 |
| Lutein Complex Supplementation Increases Ocular Blood Flow Biomarkers in Healthy Subjects 2019 · lutein phytochemicals complex · Healthy women, mean age 36.8 ± 12.1 years | 2 mg | 10 mg | 3 weeks | 16 |
| Oral Antioxidant and Lutein/Zeaxanthin Supplements Slow Geographic Atrophy Progression to the Fovea in Age-Related Macular Degeneration 2025 · AREDS2 lutein/zeaxanthin plus DHA/EPA · Adults aged 50–85 with large drusen in both eyes or late AMD in one eye and large drusen in the fellow eye | 2 mg | 10 mg | 5 years | — |